Chromosomal band gains and losses by CGH microarray
| Band . | Imbalance . | Frequency, no. (%) . | Genes involved* . |
|---|---|---|---|
| 22q13.32-33 | Gain | 8/14 (67) | CHKB, SBF1 |
| 14q32.33 | Gain | 5/14 (36) | — |
| Xq28 | Gain | 5/14 (36) | TAZ |
| 10q26.13 | Gain | 4/14 (29) | — |
| 16p13.3 | Gain | 4/14 (29) | RHOT2, RAB40C |
| 17q25 | Gain | 4/14 (29) | SYNGR2, WBP2 |
| 16q21-24 | Gain | 3/14 (21) | PLCG2 |
| 1p36 | Gain | 2/14 (14) | MIB2, SDF4 |
| 6p21.33 | Gain | 2/14 (14) | HLA-DMA, HLA-E, HLA-H, HLA-A, HLA-B |
| 6p22.1 | Gain | 2/14 (14) | HIST1H2 cluster |
| 8q24.3 | Gain | 2/14 (14) | — |
| Xp11.23 | Gain | 2/14 (14) | OTUD5 |
| 11p15.5 | Gain | 2/14 (14) | IFITM family genes |
| 22q11.21 | Loss | 2/14 (14) | PRAME; described as a polymorphism resulting from CNV_53983, CNV_35989, and CNV_53720 |
| Band . | Imbalance . | Frequency, no. (%) . | Genes involved* . |
|---|---|---|---|
| 22q13.32-33 | Gain | 8/14 (67) | CHKB, SBF1 |
| 14q32.33 | Gain | 5/14 (36) | — |
| Xq28 | Gain | 5/14 (36) | TAZ |
| 10q26.13 | Gain | 4/14 (29) | — |
| 16p13.3 | Gain | 4/14 (29) | RHOT2, RAB40C |
| 17q25 | Gain | 4/14 (29) | SYNGR2, WBP2 |
| 16q21-24 | Gain | 3/14 (21) | PLCG2 |
| 1p36 | Gain | 2/14 (14) | MIB2, SDF4 |
| 6p21.33 | Gain | 2/14 (14) | HLA-DMA, HLA-E, HLA-H, HLA-A, HLA-B |
| 6p22.1 | Gain | 2/14 (14) | HIST1H2 cluster |
| 8q24.3 | Gain | 2/14 (14) | — |
| Xp11.23 | Gain | 2/14 (14) | OTUD5 |
| 11p15.5 | Gain | 2/14 (14) | IFITM family genes |
| 22q11.21 | Loss | 2/14 (14) | PRAME; described as a polymorphism resulting from CNV_53983, CNV_35989, and CNV_53720 |
—indicates not applicable.
Data are the deregulated genes located in the corresponding cytoband. The deregulated genes belong to the NMZL signature (FDR < 0.05 in the NMZL vs RLN comparison, all NMZL cases included).